Research Use Only · Dosing data compiled from published literature · Not for human or veterinary use

Melanotan-1 Dosage & Reconstitution

Body Protection Compound 157, PL 14736. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: preclinical.

1Set Up Your Mix

5 mg/mL · 5000 mcg/mL

Your Answer — Melanotan-1

10 mg in 2 mL
10Draw To This Line
0.1That's This Many mL
20Doses In The Vial
0102030405060708090100 U-100 syringe · 1 mL · 100 units draw to 10
10 mg ÷ 2 mL = 5 mg/mL  →  500 mcg ÷ 5 mg/mL = 0.1 mL  →  × 100 = 10 units
Looks good. Draw to 10 units on a 1 mL syringe. That is an easy amount to measure, and this vial gives you 20 doses.
When to dose
Time of dayNo particular time of day has been established.
FoodNo fasting requirement has been established.

The studies behind this compound did not test timing or food state as variables, so we are not going to invent a rule. Pick a time you can keep to consistently.

2Week-By-Week Plan — Melanotan-1

Loading then maintenance
WhenDoseHow OftenHow Many mLDraw ToNumber Of DosesPeptide Used
Days 1-10
loading phase
500 mcg daily 0.1 mL 10 u 11 5.5 mg
Maintenance
twice weekly once the response is established
500 mcg twice weekly 0.1 mL 10 u 8 4 mg
Time until the top dose
Around 2 weeks to the maintenance phase
Peptide used getting there
5.5 mg
Vials you'll need
1 × 10 mg
Once you're at the top dose
4 mg / 4 wk · 0.4 vials
Where this plan came from
A commonly used protocol
Where this came from: A loading phase to build response, then reduced frequency. Melanotan-1 is more receptor-selective than Melanotan II. Reported figures come from community protocols, not from a trial of this route.

3Common Doses — Melanotan-1

worked out for your mix
LevelDoseHow OftenHow Many mLDraw ToDoses In Vial
Low reported 250 mcg daily 0.05 mL 5 u 40 doses
Commonly reported 500 mcg daily during loading 0.1 mL 10 u 20 doses
Maintenance 500 mcg twice weekly 0.1 mL 10 u 20 doses
Approved implant equivalent16 mg implant / 2 months not comparable Set by body weight — can't be turned into a single amount to draw
Please read this. These numbers come from published research. They are here as reference, not as instructions. A lot of them come from lab studies rather than studies in people, and some of these peptides have never been given to a person at all.

About BPC-157

Tissue Repair & Recovery
Also known as
Afamelanotide, MT-1, NDP-MSH
Class
Cosmetic & Dermal
Route
Subcutaneous
Half-life
~30 min (implant form is sustained release)
Evidence tier
Clinical

A selective alpha-MSH analogue. Approved in some jurisdictions as afamelanotide for erythropoietic protoporphyria, but as a sustained-release implant rather than a reconstituted injection, so the approved dosing does not translate directly. Distinct from Melanotan II, which is less receptor-selective and carries different reported effects.

Buy Melanotan-1

Common Questions — Melanotan-1

How much bacteriostatic water do I add to a 10 mg vial of Melanotan-1?

Adding 2 mL of bacteriostatic water to a 10 mg vial gives 5 mg/mL. That is the mix every number on this page is worked out from — change the water figure in the calculator and all the draw amounts update.

What dose of Melanotan-1 is used in research?

Published and reported figures for Melanotan-1 run from 250 mcg to 500 mcg, typically daily. This site lists each figure with the source it came from rather than giving a single recommended number.

How many units on the syringe is a 250 mcg dose of Melanotan-1?

At 5 mg/mL, a 250 mcg dose is 5 units on a 1 mL U-100 insulin syringe. One vial at that mix gives about 40 doses.

How strong is the evidence behind these Melanotan-1 doses?

Melanotan-1 is graded clinical. Human trial or approved-label dosing has been published for this compound. We grade every compound on this site so you can weigh the numbers accordingly — the full method is on our editorial policy page.

Where These Numbers Come From

Clinical — Human trial or approved-label dosing published
Afamelanotide for erythropoietic protoporphyria Langendonk JG, et al. New England Journal of Medicine, 2015
The trial behind the approved implant. Note the route is not the same as reconstituted injection.
Find on PubMed ↗
Alpha-MSH analogues and melanocortin receptor selectivity Melanocortin pharmacology reviews
Explains why MT-1 and MT-2 behave differently.
Find on PubMed ↗

Newest Studies —

Not reviewed by us. This list is pulled straight from Europe PMC as papers are published. Nobody has checked whether these are any good, or whether they change anything above. The dose numbers on this page only ever change after a person reviews the evidence.

Need this on one page to print, screenshot or send?

Make a dose card →

Other tissue repair & recovery peptides

Compounds in the same class, or browse the full catalogue.

KPV

The C-terminal tripeptide of α-melanocyte-stimulating hormone, studied for anti-inflammatory activity in colitis and dermatitis mo…

TB-500

A synthetic fragment of thymosin beta-4, the actin-sequestering protein. Full-length Tβ4 reached human trials for dry eye and card…

All 72 peptides

Every compound compared in one table: dose range, how often, half-life and evidence tier.